AstriVax – Strategic-Technological Analysis
33 pages · PDF · 20 August 2025 · Licensed single-user copy, watermarked to the buyer
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
AstriVax is a Belgian biotechnology venture pioneering a new approach to vaccines that could reshape Europe’s strategic health security. Founded in 2022 as a spin-off from KU Leuven’s renowned Rega Institute, the company has built a plug-and-play DNA vaccine platform designed to tackle some of the world’s most challenging viral diseases .
AstriVax’s core innovation enables the delivery of live-attenuated vaccines in a radically simpler way: using a thermostable DNA plasmid to launch a self-amplifying vaccine inside the patient .
Key questions this report answers
- How does AstriVax's plug-and-play thermostable DNA plasmid platform deliver self-amplifying, live-attenuated vaccines?
- What is the clinical and technology readiness of the platform, and how does it fit Europe's strategic health-security autonomy?
- Which research partners, funders and dual-use markets does the KU Leuven Rega Institute spin-off target?
- What capability gaps, dependencies and strategic indicators define AstriVax's path to deployment?
Inside this report
- Executive Summary
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening AstriVax, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (20 August 2025). You receive a 33-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Military Medical Tech · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →